LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

LLY

1,102.4

-2.29%↓

JNJ

225.22

-2.59%↓

ABBV

217.86

-0.41%↓

UNH

379.82

-0.69%↓

MRK

118.52

-1.23%↓

Home・Lista de Ações・Incyte Corp

Incyte Corp

Abrir

SetorSaúde

96.83 -0.65

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

96.18

Máximo

97.81

Indicadores-chave
By Trading Economics
Rendimento	4.1M 303M
Vendas	-234M 1.3B
P/E Médio do Setor	13.723 50.102
EPS	1.81
Margem de lucro	23.834
Funcionários	2,844
EBITDA	-47M 368M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+11.25% upside

Dividendos
By Dow Jones
Próximos Ganhos	28 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	362M 19B
Abertura anterior	97.48
Fecho anterior	96.83

Sentimento de Notícias

By Acuity

58%

42%

277 / 344 Ranking em Healthcare

Incyte Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de mai. de 2026, 22:47 UTC

Ganhos

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 de mai. de 2026, 20:45 UTC

Ganhos

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 de mai. de 2026, 23:31 UTC

Conversa de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 de mai. de 2026, 22:41 UTC

Conversa de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 de mai. de 2026, 22:37 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 de mai. de 2026, 22:04 UTC

Aquisições, Fusões, Aquisições de Empresas

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 de mai. de 2026, 21:12 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 de mai. de 2026, 21:00 UTC

Ganhos

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 de mai. de 2026, 20:57 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:55 UTC

Ganhos

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

28 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

28 de mai. de 2026, 20:48 UTC

Ações em Alta

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 de mai. de 2026, 20:34 UTC

Ganhos

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 de mai. de 2026, 20:31 UTC

Ganhos

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 de mai. de 2026, 20:28 UTC

Ganhos

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 de mai. de 2026, 20:26 UTC

Ganhos

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Membership Fees $1.37B

28 de mai. de 2026, 20:20 UTC

Ganhos

Costco 3Q Net Sales $69.15B

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 de mai. de 2026, 20:19 UTC

Ganhos

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 de mai. de 2026, 20:17 UTC

Ganhos

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparação entre Pares

Variação de preço

Incyte Corp Previsão

Preço-alvo

By TipRanks

11.25% parte superior

Previsão para 12 meses

Média 108.29 USD 11.25%

Máximo 135 USD

Mínimo 75 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Incyte Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

19 ratings

Comprar

Manter

Vender

Com base em 19 analistas que deram avaliações de ações para Incyte Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

277 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation